Miranda Smith

Dr. Miranda Smith

Australian Partnership for Preparedness Research on Infectious Disease Emergencies, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JEJulian H Elliott
Julian H Elliott
FWFiona Wightman
Fiona Wightman
ASAjantha Solomon
Ajantha Solomon
KGKhader Ghneim
Khader Ghneim
JAJeffrey Ahlers
Jeffrey Ahlers
Sharon LewinSharon Lewin
Sharon Lewin
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintaining HIV latency and histone deacetylase inhibitors (HDACi) may reverse latency by activating HIV transcription from latently infected CD4+ T-cells. We performed a single arm, open label, proof-of-concept study in which vorinostat, a pan-HDACi, was administered 400 mg orally once daily for 14 days to 20 HIV-infected individuals on suppressive antiretroviral therapy (ART). The primary endpoint was change in cell associated unspliced (CA-US) HIV RNA in total CD4+ T-cells from blood at day 14. The study is registered at ClinicalTrials.gov (NCT01365065). Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations. CA-US HIV RNA in blood increased significantly in 18/20 patients (90%) with a median fold change from baseline to peak value of 7.4 (IQR 3.4, 9.1). CA-US RNA was significantly elevated 8 hours post drug and remained elevated 70 days after last dose. Significant early changes in expression of genes associated with chromatin remodeling and activation of HIV transcription correlated with the magnitude of increased CA-US HIV RNA. There were no statistically significant changes in plasma HIV RNA, concentration of HIV DNA, integrated DNA, inducible virus in CD4+ T-cells or markers of T-cell activation. Vorinostat induced a significant and sustained increase in HIV transcription from latency in the majority of HIV-infected patients. However, additional interventions will be needed to efficiently induce virus production and ultimately eliminate latently infected cells. ClinicalTrials.gov NCT01365065 The major barrier to curing HIV is the long term persistence of latently infected resting memory T-cells in HIV-infected patients on antiretroviral therapy (ART). One strategy being pursued to eliminate latently infected cells is to activate HIV production from latently infected cells with the aim of killing latently infected cells via virus induced cell death or stimulation of an HIV-specific immune response. Histone deacetylases (HDACs) are important in maintaining HIV latency. Vorinostat, an inhibitor of HDACs (HDACi) licensed for the treatment of some malignancies, has been shown in laboratory studies and a clinical study of selected individuals to disrupt HIV latency. We examined the ability of standard dose vorinostat given daily for 14 days to activate latent HIV infection in unselected HIV-infected individuals on ART. The study showed evidence of activation of latent HIV infection in 18/20 (90%) of individuals and was safe and generally well tolerated. There were significant early changes in host gene expression, which persisted during and after the period of vorinostat. No changes were seen in immune activation or number of latently infected cells. Vorinostat was able to activate latent HIV infection in most individuals. Additional interventions will be needed to eliminate latent HIV infection.

1 May 2005 in Journal of Virology
Verified
Journal Article
Closed access
CFCaroline S. Fernandez
Caroline S. Fernandez
ISIvan Stratov
Ivan Stratov
RRRobert De Rose
Robert De Rose
KWKatrina Ann Walsh
Katrina Ann Walsh
CDC. Jane Dale
C. Jane Dale
SKStephen J. Kent
Stephen J. Kent
Escape from specific T-cell responses contributes to the progression of human immunodeficiency virus type 1 (HIV-1) infection. T-cell escape viral variants are retained following HIV-1 transmission between major histocompatibility complex (MHC)-matched individuals. However, reversion to wild type can occur following transmission to MHC-mismatched hosts in the absence of cytotoxic T-lymphocyte (CTL) pressure, due to the reduced fitness of the escape mutant virus. We estimated both the strength of immune selection and the fitness cost of escape variants by studying the rates of T-cell escape and reversion in pigtail macaques. Near-complete replacement of wild-type with T-cell escape viral variants at an immunodominant simian immunodeficiency virus Gag epitope KP9 occurred rapidly (over 7 days) following infection of pigtail macaques with SHIV SF162P3 . Another challenge virus, SHIV mn229 , previously serially passaged through pigtail macaques, contained a KP9 escape mutation in 40/44 clones sequenced from the challenge stock. When six KP9-responding animals were infected with this virus, the escape mutation was maintained. By contrast, in animals not responding to KP9, rapid reversion of the K165R mutation occurred over 2 weeks after infection. The rapidity of reversion to the wild-type sequence suggests a significant fitness cost of the T-cell escape mutant. Quantifying both the selection pressure exerted by CTL and the fitness costs of escape mutation has important implications for the development of CTL-based vaccine strategies.

19 June 2016 in AIDS
Verified
Journal Article
Closed access
GKGabriela Khoury
Gabriela Khoury
JAJenny L. Anderson
Jenny L. Anderson
RFRémi Fromentin
Rémi Fromentin
WHWendy Hartogenesis
Wendy Hartogenesis
Miranda SmithMiranda Smith
Miranda Smith
Sharon LewinSharon Lewin
Sharon Lewin
Background: HIV latent infection can be established in vitro by treating resting CD4+ T cells with chemokines that bind to chemokine receptors (CKR), CCR7, CXCR3, and CCR6, highly expressed on T cells. Objective: To determine if CKR identify CD4+ T cells enriched for HIV in HIV-infected individuals receiving suppressive antiretroviral therapy (ART). Design: A cross-sectional study of CKR expression and HIV persistence in blood from HIV-infected individuals on suppressive ART for more than 3 years (n = 48). A subset of 20 individuals underwent leukapheresis and sorting of specific CD4+ T-cell subsets. Methods: We used flow cytometry to quantify CCR5, CCR6, CXCR3, and CXCR5 expression on CD4+ T cells. HIV persistence was quantified using real-time Polymerase Chain Reaction to detect total, integrated HIV DNA, 2-long terminal repeat circles and cell-associated unspliced (CA-US) HIV RNA in total CD4+ T cells from blood or sorted T-cell subsets. Associations between CKR and HIV persistence in CD4+ T cells in blood were determined using regression models and adjusted for current and nadir CD4+ T-cell counts. Results: The frequency of cells harbouring integrated HIV DNA was inversely associated with current CD4+ T-cell count and positively associated with CCR5+ CD4+ T cells, CXCR3+CCR6+ and CXCR3+CCR6– expression on total memory CD4+ T cells (P < 0.001, 0.048, 0.015, and 0.016, respectively). CXCR3+CCR6+ CM CD4+ T cells contained the highest amount of integrated HIV DNA and lowest ratio of CA-US HIV RNA to DNA compared to all T-cell subsets examined. Conclusion: CXCR3 and CCR6 coexpression defines a subset of CD4+ T cells that are preferentially enriched for HIV DNA in HIV-infected individuals on ART.

15 January 2005 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
Miranda SmithMiranda Smith
Miranda Smith
CDC. Jane Dale
C. Jane Dale
RRRobert De Rose
Robert De Rose
ISIvan Stratov
Ivan Stratov
CFCaroline S. Fernandez
Caroline S. Fernandez
SKStephen J. Kent
Stephen J. Kent
Successful human immunodeficiency virus (HIV) vaccines will need to induce effective T-cell immunity. We studied immunodominant simian immunodeficiency virus (SIV) Gag-specific T-cell responses and their restricting major histocompatibility complex (MHC) class I alleles in pigtail macaques (Macaca nemestrina), an increasingly common primate model for the study of HIV infection of humans. CD8+T-cell responses to an SIV epitope, Gag164-172KP9, were present in at least 15 of 36 outbred pigtail macaques. The immunodominant KP9-specific response accounted for the majority (mean, 63%) of the SIV Gag response. Sequencing from six macaques identified 7 newMane-Aand 13 newMane-BMHC class I alleles. One new allele,Mane-A*10, was common to four macaques that responded to the KP9 epitope. We adapted reference strand-mediated conformational analysis (RSCA) to MHC class I genotypeM. nemestrina. Mane-A*10was detected in macaques presenting KP9 studied by RSCA but was absent from non-KP9-presenting macaques. Expressed on class I-deficient cells, Mane-A*10, but not other pigtail macaque MHC class I molecules, efficiently presented KP9 to responder T cells, confirming thatMane-A*10restricts the KP9 epitope. Importantly, naïve pigtail macaques infected with SIVmac251that respond to KP9 had significantly reduced plasma SIV viral levels (log100.87 copies/ml;P= 0.025) compared to those of macaques not responding to KP9. The identification of this commonM. nemestrinaMHC class I allele restricting a functionally important immunodominant SIV Gag epitope establishes a basis for studying CD8+T-cell responses against AIDS in an important, widely available nonhuman primate species.

15 February 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
SBSonia Bastidas
Sonia Bastidas
FGFrederik Graw
Frederik Graw
Miranda SmithMiranda Smith
Miranda Smith
HKHerbert Kuster
Herbert Kuster
HGHuldrych Günthard
Huldrych Günthard
AOAnnette Oxenius
Annette Oxenius
Hyperactivation of T cells, particularly of CD8+ T cells, is a hallmark of chronic HIV 1 (HIV-1) infection. Little is known about the antigenic specificities and the mechanisms by which HIV-1 causes activation of CD8+ T cells during chronic infection. We report that CD8+ T cells were activated during in vivo HIV-1 replication irrespective of their Ag specificity. Cytokines present during untreated HIV-1 infection, most prominently IL-15, triggered proliferation and expression of activation markers in CD8+ T cells, but not CD4+ T cells, in the absence of TCR stimulation. Moreover, LPS or HIV-1–activated dendritic cells (DCs) stimulated CD8+ T cells in an IL-15–dependent but Ag-independent manner, and IL-15 expression was highly increased in DCs isolated from viremic HIV-1 patients, suggesting that CD8+ T cells are activated by inflammatory cytokines in untreated HIV-1 patients independent of Ag specificity. This finding contrasts with CD4+ T cells whose in vivo activation seems biased toward specificities for persistent Ags. These observations explain the higher abundance of activated CD8+ T cells compared with CD4+ T cells in untreated HIV-1 infection.

17 January 2012 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
Miranda SmithMiranda Smith
Miranda Smith
FWFiona Wightman
Fiona Wightman
Sharon LewinSharon Lewin
Sharon Lewin